Autotaxin in encephalitogenic CD4 T cells as a therapeutic target for multiple sclerosis
European Journal of Immunology · 2024
DOI: 10.1002/eji.202350561 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Cora L Petersen-Cherubini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Graduate Program, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an immune‐mediated inflammatory disease of the CNS. A defining characteristic of MS is the ability of autoreactive T lymphocytes to cross the blood–brain barrier and mediate inflammation within the CNS. Previous work from our lab found the gene Enpp2 to be highly upregulated in murine encephalitogenic T cells. Enpp2 encodes for the protein autotaxin, a secreted glycoprotein that catalyzes the production of lysophosphatidic acid and promotes transendothelial migration of T cells from the bloodstream into the lymphatic system. The present study sought to characterize autotaxin expression in T cells during CNS autoimmune disease and determine its potential therapeutic value. Myelin‐activated CD4 T cells upregulated expression of autotaxin in vitro, and ex vivo analysis of CNS‐infiltrating CD4 T cells showed significantly higher autotaxin expression compared with cells from healthy mice. In addition, inhibiting autotaxin in myelin‐specific T cells reduced their encephalitogenicity in adoptive transfer studies and decreased in vitro cell motility. Importantly, using two mouse models of MS, treatment with an autotaxin inhibitor ameliorated EAE severity, decreased the number of CNS infiltrating T and B cells, and suppressed relapses, suggesting autotaxin may be a promising therapeutic target in the treatment of MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Graduate Program, The Ohio State University, Columbus, Ohio, USA.
- Department of Microbial Infection and Immunity, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
- Department of Neurology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
- Department of Neuroscience, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Matthew Xin, Joshua L Deffenbaugh, Christina N Rau
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Petersen-Cherubini, C. L., Murphy, S. P., Xin, M., Liu, Y., Deffenbaugh, J. L., Jahan, I., Rau, C. N., Yang, Y., & Lovett-Racke, A. E. (2024). Autotaxin in encephalitogenic CD4 T cells as a therapeutic target for multiple sclerosis. European Journal of Immunology. https://doi.org/10.1002/eji.202350561
Vancouver
Petersen-Cherubini CL, Murphy SP, Xin M, Liu Y, Deffenbaugh JL, Jahan I, et al. Autotaxin in encephalitogenic CD4 T cells as a therapeutic target for multiple sclerosis. European Journal of Immunology. 2024. doi:10.1002/eji.202350561
BibTeX
@article{PetersenCherubini2024,
author = {Petersen-Cherubini, Cora L and Murphy, Shawn P and Xin, Matthew and Liu, Yue and Deffenbaugh, Joshua L and Jahan, Ishrat and Rau, Christina N and Yang, Yuhong and Lovett-Racke, Amy E},
title = {Autotaxin in encephalitogenic CD4 T cells as a therapeutic target for multiple sclerosis},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202350561}
}
EUVIMED